Chien, K. S., Ramdial, J. L., Qiao, W., John, R., Montalban-Bravo, G., Short, N. J., Issa, G. C., Ravandi-Kashani, F., Daver, N. G., Kadia, T. M., Kantarjian, H. M., Garcia-Manero, G., DiNardo, C. D. (2025). Phase II study evaluating olutasidenib and azacitidine in patients with
            <i>IDH1</i>
            -mutated higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasms.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps6586